Medication info

Pregabalin Capsule 25 mg (Pregabalin)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
Shinil Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a light yellow upper part and a white lower part containing white powder.
Packaging
30 capsules/bottle
Approval status
Expired

MFDS item code 201906159 · Approved 2019.08.29

This product's status changed to Expired on 2024.08.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. As this medicine is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg daily. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg daily. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg daily. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The starting dose is 75 mg twice daily (150 mg daily), and depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys in unchanged form. As clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalinᵃ 150-600 ≥30-<60: 75-300, BID or TID ≥15-<30: 25-150, BID or TID <15: 25-75, QD or BID Supplemental dose after hemodialysis: 25-100, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily ᵃ: The total daily dose (mg/day) should be divided as specified in the dosing instructions. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
As there are insufficient safety and efficacy data for children under 12 years of age and adolescent patients aged 12-17 years, use is not recommended.

Ingredients

Manufacturer
Shinil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. Additionally, it is utilized as an adjunctive treatment for partial seizures in patients with epilepsy, whether they have secondary generalized symptoms or not. Furthermore, it is effective in treating pain caused by fibromyalgia. This medication assists in pain relief and the management of neurological disorders for the patients.

How to take

Adult dose

This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. As this medicine is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg daily. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg daily. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg daily. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The starting dose is 75 mg twice daily (150 mg daily), and depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys in unchanged form. As clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalinᵃ 150-600 ≥30-<60: 75-300, BID or TID ≥15-<30: 25-150, BID or TID <15: 25-75, QD or BID Supplemental dose after hemodialysis: 25-100, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily ᵃ: The total daily dose (mg/day) should be divided as specified in the dosing instructions. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

As there are insufficient safety and efficacy data for children under 12 years of age and adolescent patients aged 12-17 years, use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if any depression or mood changes occur during treatment, it must be reported to a healthcare provider immediately. Patients allergic to any components of this medication or with specific genetic lactose metabolism disorders should not take it. Diabetic patients may need to adjust their blood sugar control medications due to weight gain. If severe allergic reactions, such as angioedema, occur, the use of this medication should be stopped immediately. Elderly patients may be at higher risk of falls or accidents due to dizziness or drowsiness when taking this medication, so caution should be exercised. Blurred vision or changes in vision may occur; if any abnormal symptoms appear, consult a healthcare provider. If this medication is stopped suddenly, withdrawal symptoms such as insomnia, headaches, and anxiety may occur, so it should be tapered off gradually according to the healthcare provider's instructions. Patients with a history of drug abuse may be at a higher risk for misuse and dependence on this medication and should be managed carefully. Patients with impaired kidney function may require dosage adjustments. Patients with severe heart conditions should exercise caution when taking this medication. Caution is warranted when taking this medication with other central nervous system depressants or opioids, as the risk of respiratory depression may increase. In early pregnancy, there is a risk of fetal malformation, so pregnant women should avoid taking this medication, and women of childbearing potential should use effective contraception. Women who are breastfeeding should consider stopping breastfeeding or discontinuing this medication, as it can be passed into breast milk and may affect the infant. This medication may cause dizziness and drowsiness; caution is advised before driving or operating machinery. Severe skin reactions may occur rarely, so if skin rashes or swelling occur, discontinue use immediately and consult a healthcare provider. In case of overdose, confusion, drowsiness, seizures, etc., may occur, and treatment such as hemodialysis may be necessary if required. Keep this medication out of the reach of children, and it is safest not to transfer it to other containers.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 207 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • depression
  • pain
  • sweating
  • vertigo
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hyperesthesia
  • restlessness
  • anxiety
  • mood swings
  • emotional blunting
  • emotional elevation
  • hallucinations
  • unusual dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory reduction
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorder
  • myoclonus
  • decreased reflexes
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • reduced motor activity
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • blurred vision
  • double vision
  • indirect vision loss
  • visual disturbances
  • visual field defects
  • photophobia
  • dryness of the eyes
  • ocular edema
  • reduced vision
  • eye pain
  • eye fatigue
  • increased tear production
  • ocular irritation
  • mydriasis
  • when vibrating
  • change in depth perception of vision
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • bradycardia
  • dysrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • shortness of breath
  • nosebleed
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal bloating
  • constipation
  • dry mouth
  • distension
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • sensations of intoxication
  • sensory disturbances
  • fatigue
  • chest tightness
  • general edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis
  • affective disorders
  • drowsiness
  • altered mental status
  • agitation
  • restlessness
  • seizures
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme
  • ataxia
  • speech disorders
  • sensory abnormalities
  • memory disorders
  • attention disorders
  • constipation
  • gastrointestinal disorders
  • bloody stools
  • increased BUN
  • dysuria
  • tinnitus
  • skin disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it is best maintained at room temperature between 15 to 30 degrees Celsius. Storing this way will maintain the medication's efficacy and prevent deterioration.

Appearance and packaging

Appearance

A hard capsule with a light yellow upper part and a white lower part containing white powder.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.